胰腺癌动物模型的比较与选择

延张励; 许小凡; 辛嘉萁; 张红

doi:10.3969/j.issn.1001-5256.2022.12.044

胰腺癌动物模型的比较与选择

DOI: 10.3969/j.issn.1001-5256.2022.12.044

延张励¹,
许小凡¹,
辛嘉萁²,
张红^{1, 3, , ,}

1.
陕西中医药大学基础医学院, 陕西西咸新区 712046
2.
慕尼黑工业大学伊莎河右岸医院胰腺病研究所, 德国慕尼黑 81675
3.
陕西省免疫炎症相关疾病中医药防治国际联合研究中心, 陕西西咸新区 712046

基金项目:

国家自然科学基金 (82174201);

国家自然科学基金 (82104815);

陕西中医药大学创新团队项目 (2019-YL14);

陕西省特支计划 (303/141020047)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：延张励负责搜集数据，撰写论文；辛嘉萁参与修改论文；张红、许小凡负责指导撰写文章并最后定稿。

详细信息

通信作者:
张红, zhangh1227@163.com

计量
- 文章访问数: 1519
- HTML全文浏览量: 1981
- PDF下载量: 153
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-16
- 录用日期: 2022-07-18
- 出版日期: 2022-12-20

Comparison and selection of animal models of pancreatic cancer

Zhangli YAN¹,
Xiaofan XU¹,
Jiaqi XIN²,
Hong ZHANG^{1, 3
, ,
,}

1.
School of Basic Medicine, Shaanxi University of Chinese Medicine, Xixian NewArea, Shaanxi 712046, China
2.
Department of Gastroenterology, Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich 81675, Germany
3.
Shaanxi International Joint Research Center for Prevention and Treatment of Immune Inflammation Related Diseases with TCM, Xixian New Hrea, Shaanxi 712046, China

Research funding:

National Natural Science Foundation of China (82174201);

National Natural Science Foundation of China (82104815);

Innovation Team Project of Shaanxi University of Traditional Chinese Medicine (2019-YL14);

Special Project in Shaanxi Province (303/141020047)

More Information

Corresponding author: ZHANG Hong, zhangh1227@163.com (ORCID: 0000-0003-1682-8171)

摘要

摘要: 胰腺癌(PC)发病隐匿、进展快、预后差，目前，其临床治疗尚无标准方案，而新的靶向治疗获益率并不明显，导致PC的死亡率极高。因此，认识PC的发生、发展机制成为目前亟待解决的首要难题，而建立可靠的PC动物模型，是深入探讨PC发生发展、侵袭、转移机制及优化有效治疗靶点的基础。目前, 大量的研究已建立了多种PC动物模型，本文现对各种常用的动物模型进行比较，为PC研究过程中动物模型的选择提供一定的参考。
- 胰腺肿瘤 /
- 疾病模型, 动物 /
- 化学, 药物 /
- 异种移植模型抗肿瘤试验
Abstract: Pancreatic cancer (PC) has the characteristics of insidious onset, rapid progression, and poor prognosis. Up to now, there are no standard clinical regimens for the treatment of PC, and the benefit rate of new targeted therapy remains at a relatively low level, which results in the high mortality rate of PC. Therefore, an understanding of the development and progression mechanisms for PC has become a difficult issue to be solved, and establishment of reliable animal models for PC is the basis for exploring the development, progression, invasion, and metastasis of PC and the optimization of effective therapeutic targets. At present, a large number of studies have established various animal models for PC, and this article compares the commonly used animal models to provide a reference for the selection of animal models in PC research.
- Pancreatic Neoplasms /
- Disease Models, Animal /
- Chemistry, Pharmaceutical /
- Xenograft Model Antitumor Assays

HTML全文

表 1 几种PC造模方式优缺点比较

Table 1. Comparison of advantages and disadvantages of several PC modeling methods

造模方式	优点	缺点
BOP诱导	费用低，操作简单易行	造模时间较长
DMBA诱导	肿瘤进展过程与人类PC相似，便于研究各个阶段PC的发展机制	操作复杂
原位移植	肿瘤生理特征、微环境符合实际	手术操作困难，动物死亡率高
异位移植	费用低，操作简单，便于观察测量肿瘤大小	无法准确模拟人类PC微环境
PDX	保留肿瘤生物学特征	建模时间长
基因工程	肿瘤转移方式与临床相似，便于研究早期病变	建模时间长，价格昂贵，难以大规模建立
类器官	高通量筛选，高特异性，高保真性	技术还未成熟，成本高

下载: 导出CSV

参考文献(40)

[1]	Chinese Society for Clinical Oncologists Expert Committee on Pancreatic Diseases, China International Exchange and Promotive Association for Medical and Health Care Expert Committee on Abdominal Neoplasms, China Medicine Education Association. Expert consensus on the MDT model of pancreatic cancer in China(2020version)[J]. J Clin Hepatol, 2020, 36(9): 1947-1951. DOI: 10.3969/j.issn.1001-5256.2020.09.007. 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会胰腺疾病专家委员会, 中国医药教育协会腹部肿瘤专家委员会. 中国胰腺癌多学科综合治疗模式专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(9): 1947-1951. DOI: 10.3969/j.issn.1001-5256.2020.09.007.
[2]	YIN H, LIU HL. Animal models of pancreatic cancer[J]. Chin J Gastroenterol, 2015, 20(2): 109-112. DOI: 10.3969/j.issn.1008-7125.2015.02.010. 尹航, 刘海林. 胰腺癌的动物模型研究[J]. 胃肠病学, 2015, 20(2): 109-112. DOI: 10.3969/j.issn.1008-7125.2015.02.010.
[3]	WEI JS, ZHANG Y, REN HJ, et al. The biological characteristics related study of BOP-Induced syrian golden hamsters pancreatic cancer[J]. J Nanjing Med Univ(Natural Sciences), 2013, 33(12): 1669-1673. DOI: 10.7655/NYDXBNS20131205. 卫积书, 张烨, 任华建, 等. BOP诱导叙利亚仓鼠胰腺癌动物模型建立和相关生物学特性的研究[J]. 南京医科大学学报(自然科学版), 2013, 33(12): 1669-1673. DOI: 10.7655/NYDXBNS20131205.
[4]	MA QS, ZHANG XM, SHEN CY, et al. Establishment of animal model of pancreatic carcinoma in Syrian golden hamsters[J]. J North Sichuan Med Coll, 2014, 29(4): 351-354. DOI: 10.3969/j.issn.1005-3697.2014.04.08. 马青松, 张小明, 沈成义, 等. 金黄地鼠胰腺癌动物模型的建立[J]. 川北医学院学报, 2014, 29(4): 351-354. DOI: 10.3969/j.issn.1005-3697.2014.04.08.
[5]	TAKEUCHI Y, TAKAHASHI M, SAKANO K, et al. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma[J]. Carcinogenesis, 2007, 28(8): 1692-1696. DOI: 10.1093/carcin/bgm095.
[6]	CAO W, ZHOU GX, ZHANG HF, et al. Effects of different doses of BOP on induced hamster modelof pancreatic cancer and related gene expression[J]. Chin J Pancreatol, 2014, 14(4): 230-234. DOI: 10.3760/cma.j.issn.1674-1935.2014.04.005. 曹维, 周国雄, 张海峰. 不同剂量N-亚硝基双-2-氧丙基诱导仓鼠胰腺癌的成模效果及对相关基因表达的影响[J]. 中华胰腺病杂志, 2014, 14(4): 239-234. DOI: 10.3760/cma.j.issn.1674-1935.2014.04.005.
[7]	REN Y, HOU XP, LI D, et al. DMBA induces pancreatic tumorigenesis in rats[J]. World Chin J Digestol, 2015, 23(29): 4700-4705. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201529017.htm 任宇, 侯晓朴, 李丹, 等. DMBA对大鼠胰腺肿瘤发生的影响[J]. 世界华人消化杂志, 2015, 23(29): 4700-4705. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201529017.htm
[8]	XIA SJ. Application of microRNAs in the occurrence and early diagnosis of pancreatic cancer[D]. Jinan: Shandong University, 2013. 夏蜀珺. microRNAs在胰腺癌发生与早期诊断中的应用[D]. 济南: 山东大学, 2013.
[9]	REN Y, HOU XP, LI D, et al. The effect of small dose DMBA on rat pancreatic tumorigenesis[J]. J Cap Med Univ, 2015, 36(6): 936-941. DOI: 10.3969/j.issn.1006-7795.2015.06.018. 任宇, 侯晓朴, 李丹, 等. 小剂量DMBA对大鼠胰腺的致瘤作用[J]. 首都医科大学学报, 2015, 36(6): 936-941. DOI: 10.3969/j.issn.1006-7795.2015.06.018.
[10]	DING MN, DENG CL, LI Y, et al. Effect of silencing Tiam1 on growth of xenografts with pancreatic cancer in nude mice[J]. Chin J Gerontol, 2020, 40(4): 843-846. DOI: 10.3969/j.issn.1005-9202.2020.04.053. 丁米娜, 邓春玲, 李月, 等. Tiam1基因沉默对胰腺癌细胞裸鼠移植瘤生长的影响[J]. 中国老年学杂志, 2020, 40(4): 843-846. DOI: 10.3969/j.issn.1005-9202.2020.04.053.
[11]	FU X, GUADAGNI F, HOFFMAN RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens[J]. Proc Natl Acad Sci U S A, 1992, 89(12): 5645-5649. DOI: 10.1073/pnas.89.12.5645.
[12]	WANG ZH, CHEN JJ, HUANG CJ, et al. Establishment of orthotopic transplatation model of human pancreatic cancer in nude mice[J]. Zhejiang Med J, 2016, 38(15): 1238-1240, 1249. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJYE201615009.htm 王兆洪, 陈晶晶, 黄崇杰, 等. 小鼠人胰腺癌原位移植瘤模型建立及其MicroPET检测研究[J]. 浙江医学, 2016, 38(15): 1238-1240, 1249. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJYE201615009.htm
[13]	ZHANG H, ZHANG CQ, ZHAO Y, et al. Establishment and characterization of a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer[J]. Acta Lab Anim Scientia Sinica, 2018, 26(3): 296-301. DOI: 10.3969/j.issn.1005-4847.2018.03.005. 张贺, 张彩勤, 赵勇, 等. 基于临床手术标本的胰腺癌原位移植模型建立及评价[J]. 中国实验动物学报, 2018, 26(3): 296-301. DOI: 10.3969/j.issn.1005-4847.2018.03.005.
[14]	CONROY T, BACHET JB, AYAV A, et al. Current standards and new innovative approaches for treatment of pancreatic cancer[J]. Eur J Cancer, 2016, 57: 10-22. DOI: 10.1016/j.ejca.2015.12.026.
[15]	SPEAR S, MCNEISH IA, CAPASSO M. Generation of orthotopic pancreatic tumors and ex vivo characterization of tumor-infiltrating T cell cytotoxicity[J]. J Vis Exp, 2019, 154: e60622. DOI: 10.3791/60622.
[16]	JIANG YJ, LEE CL, WANG Q, et al. Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel[J]. World J Gastroenterol, 2014, 20(28): 9476-9485. DOI: 10.3748/wjg.v20.i28.9476.
[17]	GUO S, GAO S, LIU R, et al. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer[J]. FASEB J, 2019, 33(1): 873-884. DOI: 10.1096/fj.201800617R.
[18]	SHEN ZT, WU XH, WANG L, et al. Effects of gemcitabine on radiosensitization, apoptosis, and Bcl-2 and Bax protein expression in human pancreatic cancer xenografts in nude mice[J]. Genet Mol Res, 2015, 14(4): 15587-15596. DOI: 10.4238/2015.December.1.10.
[19]	ZHANG L, HOU YH, LI CM, et al. Comparison of anti-tumor effects between MUC1-GEM-PBCA-NP and CA199-GEM-PBCA-NP on pancreatic cancer xenografts in nude mice[J]. Shandong Med J, 2020, 60(36): 42-45. DOI: 10.3969/j.issn.1002-266X.2020.36.010. 张林, 侯艳红, 李春梅, 等. MUC1-GEM-PBCA-NP、CA199-GEM-PBCA-NP静注对裸鼠胰腺癌种植瘤的抑制作用对比观察[J]. 山东医药, 2020, 60(36): 42-45. DOI: 10.3969/j.issn.1002-266X.2020.36.010.
[20]	ZHANG FY, ADILA YKP, ZHAO JM, et al. New advances in the treatment of pancreatic cancer by targeting tumor microenvironment[J]. J Clin Hepatol, 2021, 37(9): 2246-2248. DOI: 10.3969/j.issn.1001-5256.2021.09.049. 张飞宇, 阿迪拉·亚克普, 赵金明, 等. 靶向肿瘤微环境治疗胰腺癌的新进展[J]. 临床肝胆病杂志, 2021, 37(9): 2246-2248. DOI: 10.3969/j.issn.1001-5256.2021.09.049.
[21]	CAI W, RATNAYAKE R, GERBER MH, et al. Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model[J]. Invest New Drugs, 2019, 37(2): 364-374. DOI: 10.1007/s10637-018-0647-0.
[22]	PHAM K, DELITTO D, KNOWLTON AE, et al. Isolation of pancreatic cancer cells from a patient-derived xenograft model allows for practical expansion and preserved heterogeneity in culture[J]. Am J Pathol, 2016, 186(6): 1537-1546. DOI: 10.1016/j.ajpath.2016.02.009.
[23]	KHALAILEH A, DREAZEN A, KHATIB A, et al. Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer[J]. Cancer Res, 2013, 73(6): 1811-1820. DOI: 10.1158/0008-5472.CAN-12-2014.
[24]	PERETS R, GREENBERG O, SHENTZER T, et al. Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring[J]. Oncologist, 2018, 23(5): 566-572. DOI: 10.1634/theoncologist.2017-0467.
[25]	KIM MP, LI X, DENG J, et al. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis[J]. Cancer Discov, 2021, 11(8): 2094-2111. DOI: 10.1158/2159-8290.CD-20-1228.
[26]	HUANG PH, LU PJ, DING LY, et al. TGFβ promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1[J]. Oncogene, 2017, 36(16): 2202-2214. DOI: 10.1038/onc.2016.378.
[27]	SALAYMEH Y, FARAGO M, SEBBAN S, et al. Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice[J]. Life Sci Alliance, 2020, 3(5): e202000661. DOI: 10.26508/lsa.202000661.
[28]	RANGARAJAN A, WEINBERG RA. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice[J]. Nat Rev Cancer, 2003, 3(12): 952-959. DOI: 10.1038/nrc1235.
[29]	PRINCIPE DR, OVERGAARD NH, PARK AJ, et al. KRASG12D and TP53R167H cooperate to induce pancreatic ductal adenocarcinoma in sus scrofa pigs[J]. Sci Rep, 2018, 8(1): 12548. DOI: 10.1038/s41598-018-30916-6.
[30]	LIU TT. Application of genetic engineering on gene therapy[J]. Hainan Med J, 2021, 32(4): 503-506. DOI: 10.3969/j.issn.1003-6350.2021.04.026. 刘婷婷. 基因工程技术在基因治疗中的应用进展[J]. 海南医学, 2021, 32(4): 503-506. DOI: 10.3969/j.issn.1003-6350.2021.04.026.
[31]	SHARMA SV, HABER DA, SETTLEMAN J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents[J]. Nat Rev Cancer, 2010, 10(4): 241-253. DOI: 10.1038/nrc2820.
[32]	OSUNA DE LA PEÑA D, TRABULO S, COLLIN E, et al. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology[J]. Nat Commun, 2021, 12(1): 5623. DOI: 10.1038/s41467-021-25921-9.
[33]	MANOLIO TA, FOWLER DM, STARITA LM, et al. Bedside back to bench: Building bridges between basic and clinical genomic research[J]. Cell, 2017, 169(1): 6-12. DOI: 10.1016/j.cell.2017.03.005.
[34]	DORRELL C, ERKER L, LANXON-COOKSON KM, et al. Surface markers for the murine oval cell response[J]. Hepatology, 2008, 48(4): 1282-1291. DOI: 10.1002/hep.22468.
[35]	BOJ SF, HWANG CI, BAKER LA, et al. Organoid models of human and mouse ductal pancreatic cancer[J]. Cell, 2015, 160(1-2): 324-338. DOI: 10.1016/j.cell.2014.12.021.
[36]	HUANG L, HOLTZINGER A, JAGAN I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids[J]. Nat Med, 2015, 21(11): 1364-1371. DOI: 10.1038/nm.3973.
[37]	KIM J, KOO BK, KNOBLICH JA. Human organoids: model systems for human biology and medicine[J]. Nat Rev Mol Cell Biol, 2020, 21(10): 571-584. DOI: 10.1038/s41580-020-0259-3.
[38]	MA KX, CHEN XF, LI Y, et al. Application and prospect of tumor organoids[J]. China Cancer, 2022, 31(4): 284-291. DOI: 10.11735/j.issn.1004-0242.2022.04.A006. 马可鑫, 陈晓芳, 李玥, 等. 肿瘤类器官的应用及展望[J]. 中国肿瘤, 2022, 31(4): 284-291. DOI: 10.11735/j.issn.1004-0242.2022.04.A006.
[39]	SHEN YH, FU J, LIU LM, et al. Effect of Qingyi Huaji Decoction combined with gemcitabine on apoptosis and expression of Bcl-2 protein of pancreastic cancer SW1990 in vivo[J]. Chin J Exp Med Formul, 2010, 16(2): 84-86. DOI: 10.3969/j.issn.1005-9903.2010.02.028. 沈晔华, 傅洁, 刘鲁明, 等. 清胰化积方联合吉西他滨对人胰腺癌SW1990移植瘤细胞凋亡及Bcl-2蛋白表达的影响[J]. 中国实验方剂学杂志, 2010, 16(2): 84-86. DOI: 10.3969/j.issn.1005-9903.2010.02.028.
[40]	SU LB, LIU LM, CHEN H, et al. Retrospective study of 232 post-operative patients with pancreatic cancer treated by modified Qingyi Huaji Formula combined with western medicine[J]. Chin J Integr Trad West Med, 2018, 38(8): 932-935. DOI: 10.7661/j.cjim.20180512.011. 宋利斌, 刘鲁明, 陈颢, 等. 清胰化积方化裁联合西药治疗232例胰腺癌术后患者回顾性研究[J]. 中国中西医结合杂志, 2018, 38(8): 932-935. DOI: 10.7661/j.cjim.20180512.011.